South Africa on Friday started vaccinating children and adolescents as part of the global Phase 3 clinical trials of China's Sinovac Biotech COVID-19 vaccine for children aged between 6 months and 17 years.
The global study will enroll 2,000 participants in South Africa and 12,000 others will be taking part in Kenya, the Philippines, Chile and Malaysia.
The first children in South Africa were inoculated at the Sefako Makgatho Health Sciences University in the capital Pretoria to kick off the trials and others will get shots at 6 different sites across the country, the Sinovac company said in a statement Friday.
The primary objective of the study is to evaluate the efficacy of two doses of the CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents," said the statement.
Efficacy will also be evaluated against hospitalization and severe COVID-19 cases, Sinovac said.
South Africa, which accounts for more than 35% of COVID-19 infections in Africa with 2.8 million confirmed cases including 84,327 deaths, and has recently battled a resurgence driven by the delta variant.
South Africa has recorded 6,270 new infections and 175 deaths in the last 24 hours.
More than 7 million people have been fully vaccinated with either the single-shot Johnson & Johnson vaccine or the two-dose Pfizer-BioNTech vaccine.
It is currently offering vaccines to all adults 18 years and older as it seeks to vaccinate at least 40 million people of its 60 million population by the end of the year but it is struggling to reach its target of vaccinating at least 300,000 people daily.
On Friday health minister Joe Phaahla announced the country would be issuing digital vaccination certificates to enable South Africans to produce these wherever they are needed.
While the government has said it will not force people to get vaccinated, some companies have already indicated that they will make vaccinations compulsory for their employees.
Various establishments like restaurants and bars would have to make their own decision on whether or not they serve unvaccinated patrons.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)